Literature DB >> 12548521

Iatrogenic and toxic myopathies.

Joern P Sieb1, Thomas Gillessen.   

Abstract

There has been increasing awareness of the adverse effects of therapeutic agents and exogenous toxins on the structure and function of muscle. The resulting clinical syndrome varies from one characterized by muscle pain to profound myalgia, paralysis, and myoglobinuria. Because toxic myopathies are potentially reversible, their prompt recognition may reduce their damaging effects or prevent a fatal outcome. Interest in the toxic myopathies, however, derives not only from their clinical importance but also from the fact that they serve as useful experimental models in muscle research. Morphological and biochemical studies have increased our understanding of the basic cellular mechanisms of myotoxicity. Toxins may produce, for instance, necrotizing, lysosomal-related, inflammatory, anti-microtubular, mitochondrial, hypokalemia-related, or protein synthesis-related muscle damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548521     DOI: 10.1002/mus.10244

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  17 in total

Review 1.  [Lipid lowering drug and other toxic myopathies].

Authors:  B G H Schoser; D Pongratz
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

Review 2.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  [Occurrence of chloroquine-induced myopathy after low-dose treatment of rheumatoid arthritis for seven years].

Authors:  A Haberl; P Fischer; D Pongratz; J P Sieb
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

4.  Drug-induced myopathy in a patient with pulmonary tuberculosis.

Authors:  Rajiv Shah; Pradhib Venkatesan
Journal:  BMJ Case Rep       Date:  2015-07-15

5.  Rhabdomyolysis After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Q Jiang; B H Zhang
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-09       Impact factor: 0.900

6.  Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.

Authors:  G J D Hengstman; H J ter Laak; W T M Vree Egberts; I E Lundberg; H M Moutsopoulos; J Vencovsky; A Doria; M Mosca; W J van Venrooij; B G M van Engelen
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

7.  Muscle pain in models of chemotherapy-induced and alcohol-induced peripheral neuropathy.

Authors:  Pedro Alvarez; Luiz F Ferrari; Jon D Levine
Journal:  Ann Neurol       Date:  2011-07       Impact factor: 10.422

8.  [Simvastatin-induced dermatomyositis].

Authors:  A Rasch; M Schimmer; C A Sander
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

9.  Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.

Authors:  A Dugué; H Bagheri; M Lapeyre-Mestre; J F Tournamille; L Sailler; G Dedieu; R Salvayre; J P Thouvenot; P Massip; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-04-28       Impact factor: 2.953

10.  Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin.

Authors:  Lisa Francis; Eduardo Bonilla; Ekaterina Soforo; Hom Neupane; Hassan Nakhla; Christine Fuller; Andras Perl
Journal:  Clin Rheumatol       Date:  2007-07-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.